acetylgalactosamine has been researched along with Hemophilia B in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbattista, M; Garagiola, I; Peyvandi, F | 1 |
| Matino, D; Sholzberg, M; Trinchero, A | 1 |
| Bagot, C; Benson, CC; Chowdary, P; Georgiev, P; Gercheva-Kyuchukova, L; Lissitchkov, T; Madigan, K; Mamonov, V; Mant, T; Mei, B; Pasi, KJ; Ragni, MV; Timofeeva, M; Van Nguyen, H; Yu, Q | 1 |
| Tiede, A | 1 |
| Nogami, K; Shima, M | 1 |
3 review(s) available for acetylgalactosamine and Hemophilia B
| Article | Year |
|---|---|
The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges.
Topics: Acetylgalactosamine; Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Blood Coagulation Factors; Clinical Trials as Topic; Coagulants; Factor IX; Factor VIII; Genetic Therapy; Hemophilia A; Hemophilia B; Hemorrhage; History, 20th Century; Humans; Infusions, Intravenous; Injections, Subcutaneous; Laboratories; Life Expectancy; Lipoproteins; RNA, Small Interfering; Severity of Illness Index | 2020 |
Thromboembolic Risks of Non-Factor Replacement Therapies in Hemophilia.
Topics: Acetylgalactosamine; Adolescent; Adult; Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Blood Coagulation Factors; Congresses as Topic; Factor VIIa; Hemophilia A; Hemophilia B; Hemorrhage; Humans; Recombinant Proteins; RNA, Small Interfering; Thromboembolism | 2017 |
New therapies using nonfactor products for patients with hemophilia and inhibitors.
Topics: Acetylgalactosamine; Animals; Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Blood Coagulation; Coagulants; Hemophilia A; Hemophilia B; Hemostasis; Humans; RNA, Small Interfering; Thromboembolism | 2019 |
1 trial(s) available for acetylgalactosamine and Hemophilia B
| Article | Year |
|---|---|
Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort.
Topics: Acetylgalactosamine; Adult; Antithrombins; Hemophilia A; Hemophilia B; Humans; Male; Quality of Life; RNA, Small Interfering | 2021 |
1 other study(ies) available for acetylgalactosamine and Hemophilia B
| Article | Year |
|---|---|
Fitusiran in haemophilia: a breakthrough drug with many unknowns.
Topics: Acetylgalactosamine; Factor VIII; Hemophilia A; Hemophilia B; Humans; RNA, Small Interfering | 2023 |